1stOncology™: Cancer Intelligence Service – Page 12016 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Surface Oncology to Present at Evercore ISI 2nd Annual HealthCONx Conference

On November 26, 2019 Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported that Jeff Goater, chief executive officer, and Vito Palombella, Ph.D., chief scientific officer, will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference (Press release, Surface Oncology, NOV 26, 2019, https://investors.surfaceoncology.com/news-releases/news-release-details/surface-oncology-present-evercore-isi-2nd-annual-healthconx [SID1234551708]). The presentation will take place on Wednesday, December 4th, 2019 at 8:20 a.m. ET at the Four Seasons Hotel in Boston, Mass.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The live audio and subsequent archived webcasts of the Company’s presentations will be accessible from the Company’s investor relations website, investors.surfaceoncology.com.

Replimune to Present at the Piper Jaffray 31st Annual Healthcare Conference

On November 26, 2019 Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, reported that Philip Astley-Sparke, Executive Chairman and Director of Replimune, will present and host investor meetings at the Piper Jaffray 31st Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY (Press release, Replimune, NOV 26, 2019, View Source [SID1234551707]). The Company is scheduled to present on Thursday, December 5, 2019, at 9:10 a.m. ET.

Entry into a Material Definitive Agreement

On November 26, 2019, OncoSec Medical Incorporated (the "Company") reported that it has entered into an (a) amendment, dated November 26, 2019 to the Stock Purchase Agreement and the Stockholder Agreement, each between the Company and Grand Decade Developments Limited, a British Virgin Islands limited company and a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited ("CGP), dated as of October 10, 2019 (the "CGP Amendment") and (b) amendment, dated November 26, 2019, to the Stock Purchase Agreement between the Company and Sirtex Medical US Holdings, Inc., an affiliate of CGP ("Sirtex"), dated as of October 10, 2019 (the "Sirtex Amendment" and, collectively with the CGP Amendment, the "Amendments") (Filing, 8-K, OncoSec Medical, NOV 26, 2019, View Source [SID1234551706]). The Amendments provide for, among other things, the removal of proposals from the Company’s current preliminary proxy statement for an increase in the number of the Company’s authorized outstanding shares of common stock as well as the corporate opportunity waiver. The Company’s board of directors passed resolutions to approve the corporate opportunity waiver pursuant to NRS 78.070(8).

Molecular Templates to Present at Two December Investor Conferences

On November 26, 2019 Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, reported that Eric Poma, Ph.D., Chief Executive Officer and Chief Scientific Officer, will present a corporate overview at the Evercore ISI HealthCONx Conference, and the Piper Jaffray 31st Annual Healthcare Conference (Press release, Molecular Templates, NOV 26, 2019, View Source [SID1234551705]).

Evercore ISI HealthCONx Conference
Date: Tuesday, December 3, 2019
Time: 3:05pm Eastern Time
Webcast: Click here for webcast

Piper Jaffray 31st Annual Healthcare Conference
Date: Thursday, December 5, 2019
Time: 1:50pm Eastern Time
Webcast: Click here for webcast

Magenta Therapeutics to Present at the Evercore ISI HealthCONx Conference on Tuesday, December 3rd

On November 26, 2019 Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, reported that the Company is scheduled to participate in a fireside chat at the Evercore ISI HealthCONx Conference on December 3, 2019 at 1:15 p.m. ET at the Four Seasons Hotel in Boston (Press release, Magenta Therapeutics, NOV 26, 2019, https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-present-evercore-isi-healthconx-conference [SID1234551704]).

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors and Media section of the Company’s website at www.magentatx.com. A replay of the webcast will be archived on the Magenta website for 60 days.